Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06194799 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

StatusEnrolling by Invitation
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites revised (76)v31
  2. Trial sites expanded: 71 → 76 locationsv30
  3. Study sites: 69 to 71v29
  4. Study sites revised (69)v28
  5. Study sites: 68 to 69v27
Show 25 earlier versionsHide 25 earlier versions
  1. Study sites: 65 to 68v26
  2. Study sites: 64 to 65v25
  3. Study sites: 60 to 64v24
  4. Study sites: 58 to 60v23
  5. Study sites: 52 to 58v22
  6. Study sites: 51 to 52v21
  7. Study sites: 50 to 51v20
  8. Eligibility criteria shortened, about 6 wordsv19
  9. Study sites: 46 to 50v18
  10. Study sites: 43 to 46v17
  11. Study sites: 41 to 43v16
  12. Study sites: 36 to 41v15
  13. Study sites: 34 to 36v14
  14. Study sites: 23 to 34v13
  15. Study Identification, Study Status, Oversightv12
  16. Study sites: 16 to 23v11
  17. Study sites: 14 to 16v10
  18. Study sites: 10 to 14v9
  19. Study sites: 7 to 10v8
  20. Study sites: 6 to 7v7
  21. Study sites: 5 to 6v6
  22. Re-verified, no change to tracked fieldsv5
  23. Study sites: 3 to 5v4
  24. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Study sites: 2 to 3
    • Start date changed from estimate of Apr 2024 to Apr 23, 2024
    v3
  25. Study sites: 1 to 2v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Trial Details
NCT Number NCT06194799
Lead Sponsor ACADIA Pharmaceuticals Inc.
Conditions
(from sponsor)		 Alzheimer's Disease Psychosis
Related terms Delusions, Hallucinations
Enrollment 752 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov